{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:06:37Z","timestamp":1791597997419,"version":"4.3.4"},"reference-count":244,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.anai.2026.04.015","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:13:08Z","timestamp":1776575588000},"page":"17-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comorbidities of atopic dermatitis"],"prefix":"10.1016","volume":"137","author":[{"given":"Jerry","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia Manzo","family":"Margiotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester Del","family":"Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuva","family":"Cices","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2026.04.015_bib0001","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/derm.2024.0165","article-title":"Prevalence of atopic dermatitis: a systematic review and meta-analysis","volume":"36","author":"Migliavaca","year":"2025","journal-title":"Dermatitis"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0002","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0003","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial differences in atopic dermatitis","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0004","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.anai.2024.12.005","article-title":"Worldwide prevalence of atopic dermatitis in children between 2000 and 2021: a systematic analysis","volume":"134","author":"Jin","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.anai.2026.04.015_bib0005","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3908","article-title":"Societal costs of moderate-to-severe atopic dermatitis occurring in adulthood: a Danish register-based study","volume":"101","author":"Thyssen","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0006","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0007","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/bjd.19624","article-title":"Association between atopic dermatitis and autoimmune diseases: a population-based case-control study","volume":"185","author":"Ivert","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0008","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","article-title":"Comorbidities of atopic dermatitis-what does the evidence say?","volume":"151","author":"Thyssen","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0009","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.anai.2026.04.015_bib0010","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.anai.2026.04.015_bib0011","article-title":"Atopic dermatitis and risk of autoimmune diseases: a systematic review and meta-analysis","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0012","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaci.2022.03.030","article-title":"Atopic dermatitis and risk of autoimmune conditions: population-based cohort study","volume":"150","author":"de Lusignan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0013","first-page":"202","article-title":"The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma","volume":"5","author":"Bantz","year":"2014","journal-title":"J Clin Cell Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0014","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.anai.2024.03.019","article-title":"Correlated, conflated, and confounded: the complex relationship between atopic dermatitis and food allergy","volume":"132","author":"Shaker","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"14","key":"10.1016\/j.anai.2026.04.015_bib0015","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.3390\/jcm11144232","article-title":"Atopic dermatitis and food allergy: a complex interplay what we know and what we would like to learn","volume":"11","author":"Papapostolou","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0016","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaad.2020.02.055","article-title":"Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis","volume":"84","author":"Ravnborg","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13671-011-0003-5","article-title":"Comorbidity in atopic dermatitis","volume":"1","author":"Simpson","year":"2012","journal-title":"Curr Dermatol Rep"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0018","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/medicina60010021","article-title":"Atopic march or atopic multimorbidity-overview of current research","volume":"60","author":"Mrki\u0107 Kobal","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0019","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.anai.2025.05.024","article-title":"Selected inborn errors of immunity associated with severe atopic phenotypes: implications for the practicing allergist","volume":"135","author":"Bellanti","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.anai.2026.04.015_bib0020","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jamadermatol.2023.2875","article-title":"Risk of inflammatory bowel disease in patients with atopic dermatitis","volume":"159","author":"Chiesa Fuxench","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0021","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5409\/wjcp.v5.i3.288","article-title":"Skin disease and thyroid autoimmunity in atopic South Italian children","volume":"5","author":"Pedull\u00e0","year":"2016","journal-title":"World J Clin Pediatr"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0022","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaad.2018.09.025","article-title":"Association between atopic dermatitis and autoimmune disorders in US adults and children: a cross-sectional study","volume":"80","author":"Narla","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.anai.2026.04.015_bib0023","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1542\/peds.2023-064344HD","article-title":"Atopic dermatitis and risk of autoimmunity conditions: population-based cohort study","volume":"152","author":"Lester","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.anai.2026.04.015_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1641918","article-title":"Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment","volume":"16","author":"Cheng","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jdin.2020.05.002","article-title":"Prevalence of baseline comorbidities in patients with atopic dermatitis: a population-based cohort study in Taiwan","volume":"1","author":"Cho","year":"2020","journal-title":"JAAD Int"},{"key":"10.1016\/j.anai.2026.04.015_bib0026","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.4447","article-title":"Effect of disease severity on comorbid conditions in atopic dermatitis: nationwide registry-based investigation in Finnish adults","volume":"103","author":"Kiiski","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.anai.2026.04.015_bib0027","series-title":"Autoimmunity: From Bench to Bedside","year":"2013"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0028","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/jdv.19699","article-title":"Early intervention and disease modification in atopic dermatitis-the current state of the field and barriers to progress","volume":"38","author":"Jacobson","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"18","key":"10.1016\/j.anai.2026.04.015_bib0029","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two Phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.anai.2026.04.015_bib0031","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00403-020-02165-z","article-title":"What are the highest yielding search strategy terms for systematic reviews in atopic dermatitis? A systematic review","volume":"313","author":"Ayasse","year":"2021","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"10.1016\/j.anai.2026.04.015_bib0032","article-title":"What\u2019s the risk: differentiating risk ratios, odds ratios, and hazard ratios?","volume":"12","author":"George","year":"2020","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0033","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/jid.2008.88","article-title":"\"Outside-to- inside\" (and now back to \"outside\") pathogenic mechanisms in atopic dermatitis","volume":"128","author":"Elias","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0034","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-025-00664-9","article-title":"Alopecia areata","volume":"11","author":"Ungar","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.anai.2026.04.015_bib0035","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/jid.2012.129","article-title":"Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance","volume":"132","author":"Jagielska","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0036","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0037","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bjd.12396","article-title":"T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata","volume":"169","author":"Tembhre","year":"2013","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.anai.2026.04.015_bib0038","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1111\/all.14814","article-title":"An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata","volume":"76","author":"Glickman","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2026.04.015_bib0039","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/503587","article-title":"Serum interleukin-4 and total immunoglobulin E in nonatopic alopecia areata patients and HLA-DRB1 typing","volume":"2010","author":"Attia","year":"2010","journal-title":"Dermatol Res Pract"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0040","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2020.04.138","article-title":"Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation","volume":"84","author":"Glickman","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0041","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/all.13346","article-title":"Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0042","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0043","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13223-021-00597-4","article-title":"Atopic dermatitis and risk of autoimmune diseases: a systematic review and meta-analysis","volume":"17","author":"Lu","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0044","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ced\/llac104","article-title":"Alopecia areata and risk of atopic and autoimmune conditions: population-based cohort study","volume":"48","author":"Holmes","year":"2023","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0045","doi-asserted-by":"crossref","first-page":"294","DOI":"10.25259\/IJDVL_1215_2023","article-title":"Atopic diseases and the risk of alopecia areata among pre-teens and teenagers in Taiwan","volume":"91","author":"Lu","year":"2025","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0046","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000525870","article-title":"Risk of atopic disorders in patients with chronic urticaria: a systematic review and meta-analysis","volume":"239","author":"Zhang","year":"2023","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0047","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2500\/aap.2018.39.4166","article-title":"Assessment of atopic dermatitis as a risk factor for chronic spontaneous urticaria in a pediatric population","volume":"39","author":"Kitsioulis","year":"2018","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0048","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/pai.12870","article-title":"Chronic spontaneous urticaria in children - a systematic review on interventions and comorbidities","volume":"29","author":"Cornillier","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0049","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/pai.13457","article-title":"Chronic urticaria in children - new insights from a large cohort","volume":"32","author":"Lachover-Roth","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.anai.2026.04.015_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2025.1681375","article-title":"Co-existence of chronic spontaneous urticaria with atopic dermatitis: clinical and immunological perspectives","volume":"6","author":"Toubi","year":"2025","journal-title":"Front Allergy"},{"issue":"8","key":"10.1016\/j.anai.2026.04.015_bib0051","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jocd.13263","article-title":"Association of atopic dermatitis with vitiligo: a systematic review and meta-analysis","volume":"19","author":"Acharya","year":"2020","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0052","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jid.2022.10.021","article-title":"Comorbidities in patients with vitiligo: a systematic review and meta-analysis","volume":"143","author":"Lee","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"6S","key":"10.1016\/j.anai.2026.04.015_bib0053","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1097\/DER.0000000000000841","article-title":"Cutaneous comorbidities associated with atopic dermatitis in Israel: a retrospective real-world data analysis","volume":"33","author":"Leshem","year":"2022","journal-title":"Dermatitis"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0054","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1365-2133.2012.11201.x","article-title":"Lichen sclerosus and atopy in boys: coincidence or correlation?","volume":"168","author":"Becker","year":"2013","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0055","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/LGT.0000000000000796","article-title":"Risk factors for lichen sclerosus: a case-control study of 43,000 Finnish women","volume":"28","author":"Halonen","year":"2024","journal-title":"J Low Genit Tract Dis"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0056","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.jid.2023.03.506","article-title":"500 Comorbidities in 630 male patients with lichen sclerosus: a case-control study","volume":"143","author":"Hieta","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0057","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaad.2020.12.051","article-title":"Hidradenitis suppurativa and atopic dermatitis: a 2-way association","volume":"85","author":"Sherman","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2026.04.015_bib0058","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jdin.2021.04.006","article-title":"Atopic dermatitis is associated with hidradenitis suppurativa diagnosis: a single institution retrospective cohort study","volume":"4","author":"Kaakati","year":"2021","journal-title":"JAAD Int"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0059","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000528920","article-title":"Risk of atopic diseases in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies","volume":"239","author":"Gau","year":"2023","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0060","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/bjd\/ljae230","article-title":"The role of OX40 ligand\/OX40 axis signalling in atopic dermatitis","volume":"191","author":"Guttman-Yassky","year":"2024","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0061","article-title":"Combined TNF-\u03b1 and OX40L targeting as a new treatment option for hidradenitis suppurativa","volume":"4","author":"Leeuw","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0062","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaci.2011.01.053","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2013part I: Clinical and pathologic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2026.04.015_bib0063","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.3390\/ijms23105518","article-title":"Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes","volume":"23","author":"Tsai","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0064","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0065","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1002\/ski2.29","article-title":"Can atopic eczema and psoriasis coexist? A systematic review and meta-analysis","volume":"1","author":"Cunliffe","year":"2021","journal-title":"Skin Health Dis"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0066","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000514581","article-title":"Bidirectional association between psoriasis and atopic dermatitis: a nationwide population-based cohort study","volume":"237","author":"Dai","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.anai.2026.04.015_bib0067","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?","volume":"48","author":"Guttman-Yassky","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0068","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000536143","article-title":"Atopic dermatitis severity and risk for psoriasis: a nationwide population-based study","volume":"240","author":"Lee","year":"2024","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0069","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjd.20497","article-title":"Association of atopic dermatitis and autoimmune comorbidities: is it real?","volume":"185","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2026.04.015_bib0070","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","article-title":"New insights into the pathogenesis of bullous pemphigoid: 2019 update","volume":"10","author":"Genovese","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0071","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/DER.0000000000000792","article-title":"The association of bullous pemphigoid with atopic dermatitis and allergic rhinitis-a population-based study","volume":"33","author":"Kridin","year":"2022","journal-title":"Dermatitis"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0072","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1365-2133.1998.02169.x","article-title":"Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity","volume":"138","author":"Ameglio","year":"1998","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0073","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1365-2133.1999.02907.x","article-title":"Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris","volume":"140","author":"Rico","year":"1999","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0074","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","article-title":"Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia","volume":"143","author":"Wakugawa","year":"2000","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2249.2011.04464.x","article-title":"Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid","volume":"166","author":"G\u00fcnther","year":"2011","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0076","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00403-022-02372-w","article-title":"Association between bullous pemphigoid and atopic dermatitis: a population-based case-control study in Taiwan","volume":"315","author":"Wu","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"10.1016\/j.anai.2026.04.015_bib0077","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.jaip.2024.04.005","article-title":"Pemphigoid and atopy: a case-control study in the All of Us database","volume":"12","author":"Powers","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2026.04.015_bib0078","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0079","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jaci.2020.04.010","article-title":"Epithelial barriers in allergy and asthma","volume":"145","author":"Hellings","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jaci.2025.11.016","article-title":"Skin tape strips identify age-specific immune, metabolic, and barrier dysregulation signatures in children, adolescents, and adults with allergic asthma","volume":"157","author":"Liu","year":"2026","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0081","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/all.16060","article-title":"Transcriptomic evaluation of skin tape-strips in children with allergic asthma uncovers epidermal barrier dysfunction and asthma-associated biomarkers abnormalities","volume":"79","author":"Del Duca","year":"2024","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0082","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ni.1852","article-title":"Sensing the outside world: TSLP regulates barrier immunity","volume":"11","author":"Ziegler","year":"2010","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0083","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2015.07.007","article-title":"Barrier epithelial cells and the control of Type 2 immunity","volume":"43","author":"Hammad","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0084","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.anai.2021.02.026","article-title":"Rhinitis prevalence and association with atopic dermatitis: a systematic review and meta-analysis","volume":"127","author":"Knudgaard","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S2213-2600(13)70277-7","article-title":"Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study","volume":"2","author":"Pinart","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0086","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(25)00003-7","article-title":"Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"13","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0087","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/DER.0000000000000034","article-title":"Associations of childhood eczema severity: a US population-based study","volume":"25","author":"Silverberg","year":"2014","journal-title":"Dermatitis"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0088","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.anai.2018.07.019","article-title":"Atopic dermatitis in US adults: epidemiology, association with marital status, and atopy","volume":"121","author":"Hua","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0089","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","article-title":"Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0090","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1111\/jdv.17048","article-title":"Association between atopic dermatitis and nasal polyposis: what is the evidence?","volume":"35","author":"Halling","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0091","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.2500\/ar.2013.4.0067","article-title":"The anatomical and functional relationship between allergic conjunctivitis and allergic rhinitis","volume":"4","author":"Hom","year":"2013","journal-title":"Allergy Rhinol (Providence)"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0092","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jaad.2020.11.037","article-title":"Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis","volume":"85","author":"Ravn","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0093","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40257-019-00455-5","article-title":"Ocular co-morbidities of atopic dermatitis. Part I: Associated ocular diseases","volume":"20","author":"Beck","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0094","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaophthalmol.2025.0366","article-title":"Risk of developing pediatric uveitis among patients with early-onset atopic dermatitis","volume":"143","author":"Chu","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0095","article-title":"Two cases of atopic dermatitis patients with scleral perforation after recurrent scleritis induced by scleral-sutured posterior chamber intraocular lens implantation","volume":"15","author":"Minamoto","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.anai.2026.04.015_bib0096","article-title":"Infectious necrotizing scleritis and proliferative vitreoretinopathy after scleral buckling in a patient with atopic dermatitis","volume":"22","author":"Sakata","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0097","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/jnnp.64.5.676","article-title":"Acute myelitis with hyperIgEaemia and mite antigen specific IgE: atopic myelitis","volume":"64","author":"Kira","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.anai.2026.04.015_bib0098","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2169\/internalmedicine.40.613","article-title":"Myelitis associated with atopic disorders in Japan: a retrospective clinical study of the past 20 years","volume":"40","author":"Kira","year":"2001","journal-title":"Intern Med"},{"issue":"11","key":"10.1016\/j.anai.2026.04.015_bib0099","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s10072-014-1832-3","article-title":"Atopic myelitis is not restricted to Japanese patients","volume":"35","author":"Buratti","year":"2014","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0100","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2018.03.017","article-title":"Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis","volume":"79","author":"R\u00f8nnstad","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0101","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3390\/jcm10061298","article-title":"Quality of life and psychological impact in patients with atopic dermatitis","volume":"10","author":"Talamonti","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.anai.2026.04.015_bib0102","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2147\/JAA.S404350","article-title":"Implications of atopic dermatitis on the quality of life of 6-11 years old children and caregivers (PEDI-BURDEN)","volume":"16","author":"Neri","year":"2023","journal-title":"J Asthma Allergy"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0103","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/jamadermatol.2018.4566","article-title":"Association between atopic dermatitis and suicidality: A systematic review and meta-analysis","volume":"155","author":"Sandhu","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0104","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1038\/s41380-025-03383-5","article-title":"Major depressive disorder shares systemic immune signatures and potential therapeutic targets with inflammatory skin diseases","volume":"31","author":"He","year":"2026","journal-title":"Mol Psychiatry"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0105","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1067\/mai.2001.119917","article-title":"Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response","volume":"108","author":"Straumann","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0106","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4049\/jimmunol.169.2.1021","article-title":"Eosinophils express functional IL-13 in eosinophilic inflammatory diseases","volume":"169","author":"Schmid-Grendelmeier","year":"2002","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.anai.2026.04.015_bib0107","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nm.3281","article-title":"Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis","volume":"19","author":"Noti","year":"2013","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0108","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/mi.2013.90","article-title":"Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis","volume":"7","author":"Sherrill","year":"2014","journal-title":"Mucosal Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0109","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaci.2019.11.005","article-title":"Relationship of skin barrier breakdown and eosinophilic esophagitis","volume":"145","author":"Simon","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0110","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.anai.2017.02.006","article-title":"Association between atopic manifestations and eosinophilic esophagitis: a systematic review and meta-analysis","volume":"118","author":"Gonz\u00e1lez-Cervera","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0111","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jaip.2018.05.038","article-title":"Phenotypic characterization of eosinophilic esophagitis in a large multicenter patient population from the consortium for food allergy research","volume":"6","author":"Chehade","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.anai.2026.04.015_bib0112","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/alr.21968","article-title":"Prevalence of atopic disease in patients with eosinophilic esophagitis","volume":"7","author":"Benninger","year":"2017","journal-title":"Int Forum Allergy Rhinol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0113","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jaci.2017.09.046","article-title":"Eosinophilic esophagitis (EoE) genetic susceptibility is mediated by synergistic interactions between EoE-specific and general atopic disease loci","volume":"141","author":"Martin","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0114","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/all.13244","article-title":"Evidence of an abnormal epithelial barrier in active, untreated and corticosteroid-treated eosinophilic esophagitis","volume":"73","author":"Simon","year":"2018","journal-title":"Allergy"},{"issue":"25","key":"10.1016\/j.anai.2026.04.015_bib0115","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0116","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","article-title":"Major comorbidities of atopic dermatitis: beyond allergic disorders","volume":"19","author":"Paller","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0117","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1159\/000505290","article-title":"The bidirectional association between inflammatory bowel disease and atopic dermatitis: a systematic review and meta-analysis","volume":"236","author":"Shi","year":"2020","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0118","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jaad.2020.05.130","article-title":"Bidirectional relationship between atopic dermatitis and inflammatory bowel disease: a systematic review and meta-analysis","volume":"83","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0119","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.anai.2026.04.015_bib0120","unstructured":"ClinicalTrials.gov. A phase 2, multi-center, randomized, double-blind, placebo-controlled parallel-group study to evaluate the efficacy and safety of dupilumab therapy in patients with moderately to severely active ulcerative colitis with an eosinophilic phenotype. Accessed February 22, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05731128"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0121","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0122","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/jdv.14673","article-title":"Immune response patterns in non-communicable inflammatory skin diseases","volume":"32","author":"Eyerich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0123","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1684\/ejd.2021.4168","article-title":"Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis","volume":"32","author":"Chester","year":"2022","journal-title":"Eur J Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2026.04.015_bib0124","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jid.2022.05.171","article-title":"164 Association between atopic dermatitis and celiac disease: a systematic review and meta-analysis","volume":"142","author":"Khan","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.anai.2026.04.015_bib0125","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2147\/CCID.S533378","article-title":"Celiac disease and skin diseases: a bidirectional Mendelian randomization study","volume":"18","author":"Ge","year":"2025","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0126","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s42003-024-07416-7","article-title":"An atlas of the shared genetic architecture between atopic and gastrointestinal diseases","volume":"7","author":"Qi","year":"2024","journal-title":"Commun Biol"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0127","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2016.08.047","article-title":"Autoimmune diseases in adults with atopic dermatitis","volume":"76","author":"Andersen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2026.04.015_bib0128","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.3390\/ijerph110808112","article-title":"Atopic diseases and systemic lupus erythematosus: an epidemiological study of the risks and correlations","volume":"11","author":"Hsiao","year":"2014","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0129","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10067-024-06900-z","article-title":"Systemic lupus erythematosus and atopic dermatitis: a two sample Mendelian randomization study","volume":"43","author":"Xia","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"14","key":"10.1016\/j.anai.2026.04.015_bib0130","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1177\/0961203314543920","article-title":"Increased Incidence of juvenile onset systemic lupus erythematosus in children with atopic dermatitis","volume":"23","author":"Wei","year":"2014","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0131","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.5826\/dpc.1503a5064","article-title":"Atopic dermatitis and autoimmune connective tissue diseases: systematic review and meta-analysis","volume":"15","author":"Naassan","year":"2025","journal-title":"Dermatol Pract Concept"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0132","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/jpgm.JPGM_1270_20","article-title":"Association of atopic dermatitis with an increased risk of systemic lupus erythematosus: a systematic review and meta-analysis","volume":"67","author":"Ponvilawan","year":"2021","journal-title":"J Postgrad Med"},{"issue":"1S","key":"10.1016\/j.anai.2026.04.015_bib0133","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/DER.0000000000000781","article-title":"Atopic dermatitis is a risk factor for rheumatoid arthritis: a systematic review and meta-analysis","volume":"32","author":"Rittiphairoj","year":"2021","journal-title":"Dermatitis"},{"issue":"11","key":"10.1016\/j.anai.2026.04.015_bib0134","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.61.11.968","article-title":"Atopic disorders in ankylosing spondylitis and rheumatoid arthritis","volume":"61","author":"Rudwaleit","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0135","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jaad.2022.12.025","article-title":"Juvenile idiopathic arthritis in children and adolescents with atopic dermatitis: a Finnish nationwide registry study","volume":"88","author":"Keskitalo","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0136","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12969-016-0074-8","article-title":"Epidemiology and risk of juvenile idiopathic arthritis among children with allergic diseases: a nationwide population-based study","volume":"14","author":"Lin","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0137","article-title":"The cross-talk between atopic dermatitis and diabetes mellitus: A meta-analysis","volume":"13","author":"Mirghani","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0138","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s00125-003-1108-6","article-title":"Atopic eczema in early childhood could be protective against type 1 diabetes","volume":"46","author":"Rosenbauer","year":"2003","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0139","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/bjd.15727","article-title":"Atopic dermatitis and risk of hypertension, type 2 diabetes, myocardial infarction and stroke in a cross-sectional analysis from the Canadian Partnership for Tomorrow Project","volume":"177","author":"Drucker","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0140","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/j.jaad.2023.04.073","article-title":"Association of atopic dermatitis with Graves\u2019 disease and Hashimoto\u2019s thyroiditis: a case-control study in the All of Us research program","volume":"89","author":"Joshi","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0141","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations","volume":"132","author":"Chu","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0142","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00403-019-01890-4","article-title":"Atopic dermatitis and autoimmunity: the occurrence of autoantibodies and their association with disease severity","volume":"311","author":"Holmes","year":"2019","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0143","doi-asserted-by":"crossref","first-page":"298","DOI":"10.5114\/reum.2017.72627","article-title":"Antinuclear antibodies in autoimmune and allergic diseases","volume":"55","author":"Grygiel-G\u00f3rniak","year":"2017","journal-title":"Reumatologia"},{"key":"10.1016\/j.anai.2026.04.015_bib0144","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1167890","article-title":"Dermatologic manifestations of thyroid disease: a literature review","volume":"14","author":"Cohen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MCG.0000000000001267","article-title":"Celiac disease: extraintestinal manifestations and associated conditions","volume":"54","author":"Therrien","year":"2020","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0146","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.3390\/ijms23062995","article-title":"Micronutrient improvement of epithelial barrier function in various disease states: a case for adjuvant therapy","volume":"23","author":"DiGuilio","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0147","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.anai.2026.04.015_bib0148","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40262-024-01419-7","article-title":"Pharmacokinetics and pharmacodynamics of systemic corticosteroids in autoimmune and inflammatory diseases: a review of current evidence","volume":"63","author":"M\u00f6hlmann","year":"2024","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0149","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.anai.2023.11.020","article-title":"Diversity of atopic dermatitis and selection of immune targets","volume":"132","author":"Rothenberg-Lausell","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0151","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.anai.2025.06.020","article-title":"New treatments in atopic dermatitis update","volume":"135","author":"Gallagher","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2026.04.015_bib0152","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102707","article-title":"Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus","volume":"123","author":"Lu","year":"2021","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.anai.2026.04.015_bib0153","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.anai.2026.04.015_bib0154","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force Part 1: Towards a new management algorithm","volume":"37","author":"van Geel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.anai.2026.04.015_bib0155","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jid.2020.12.028","article-title":"Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study","volume":"141","author":"Seneschal","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0156","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2010.03.037","article-title":"Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial","volume":"65","author":"Kuhn","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.anai.2026.04.015_bib0157","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1346-8138.2008.00552.x","article-title":"Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study","volume":"35","author":"Stefanaki","year":"2008","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0158","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1365-2133.2006.07446.x","article-title":"Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus","volume":"155","author":"Hengge","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2026.04.015_bib0159","unstructured":"ClinicalTrials.gov. Pilot study evaluating the efficacy of a topical PDE4 inhibitor for morphea. Accessed February 21, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03351114"},{"key":"10.1016\/j.anai.2026.04.015_bib0160","unstructured":"ClinicalTrials.gov. A double-blind, randomized bilateral study of the safety and efficacy of AN2728 ointment, 5%, versus ointment vehicle in the treatment of patients with plaque type psoriasis. Accessed February 17, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT00759161"},{"key":"10.1016\/j.anai.2026.04.015_bib0161","unstructured":"ClinicalTrials.gov. A double-blind, randomized, 12 week, bilateral study of the safety and efficacy of AN2728 ointment B, 2% and 0.5%, versus ointment B vehicle in the treatment of patients with plaque type psoriasis. Accessed February 17, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT01029405"},{"key":"10.1016\/j.anai.2026.04.015_bib0162","unstructured":"ClinicalTrials.gov. A double-blind, randomized, 12 week, bilateral study of the safety and efficacy of AN2728 ointment, 5%, versus ointment vehicle in the treatment of patients with plaque type psoriasis. Accessed February 17, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT00755196"},{"key":"10.1016\/j.anai.2026.04.015_bib0163","unstructured":"ClinicalTrials.gov. Study of efficacy, safety and tolerability of crisaborole and PF-07038124 with and without NBUVB in vitiligo: a phase 2A randomized, double-blind, vehicle-controlled clinical trial. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05298033"},{"key":"10.1016\/j.anai.2026.04.015_bib0164","unstructured":"ClinicalTrials.gov. Phase 2 double-blind randomized placebo controlled trial of topical crisaborole in patients with mild-to-moderate alopecia areata. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04299503"},{"key":"10.1016\/j.anai.2026.04.015_bib0165","unstructured":"Food and Drug Administration. Labels and approval history: roflumilast cream (ZORYVE) \u2013 prescribing information. Accessed February 21, 2026. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215985s007lbl.pdf"},{"issue":"16","key":"10.1016\/j.anai.2026.04.015_bib0166","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two Phase 3, randomized, controlled trials of Ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2026.04.015_bib0167","unstructured":"ClinicalTrials.gov. A phase 2, single-blind, intraindividual study to evaluate the efficacy of Ruxolitinib 1.5% cream in adult subjects with discoid lupus erythematosus. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06261021"},{"key":"10.1016\/j.anai.2026.04.015_bib0168","unstructured":"ClinicalTrials.gov. Exploratory study of Ruxolitinib cream for the treatment of discoid lupus erythematosus. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04908280"},{"key":"10.1016\/j.anai.2026.04.015_bib0169","unstructured":"ClinicalTrials.gov. A double-blind, vehicle-controlled, rising dose, safety, tolerability, pharmacokinetic and preliminary efficacy study of Ruxolitinib phosphate cream when applied to patients with plaque psoriasis. Accessed February 17, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT00820950"},{"key":"10.1016\/j.anai.2026.04.015_bib0170","unstructured":"ClinicalTrials.gov. An open label, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and preliminary efficacy study of Ruxolitinib when applied to patients with plaque psoriasis involving 2-20% body surface area (BSA). Accessed February 17, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT00617994"},{"key":"10.1016\/j.anai.2026.04.015_bib0171","unstructured":"ClinicalTrials.gov. A double-blind, randomized, vehicle-controlled dose ranging study of the effect of INCB018424 phosphate cream when applied to patients with plaque psoriasis. Accessed February 17, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT00778700"},{"key":"10.1016\/j.anai.2026.04.015_bib0172","unstructured":"ClinicalTrials.gov. A phase 3, double-blind, randomized, vehicle-controlled, efficacy and safety study of Ruxolitinib cream in participants with hidradenitis suppurativa (TRuE-HS1). Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06958211"},{"key":"10.1016\/j.anai.2026.04.015_bib0173","unstructured":"ClinicalTrials.gov. A phase 3, double-blind, randomized, vehicle-controlled, efficacy and safety study of Ruxolitinib cream in participants with hidradenitis suppurativa (TRuE-HS2). Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06958211"},{"key":"10.1016\/j.anai.2026.04.015_bib0174","unstructured":"ClinicalTrials.gov. INCB018424 in the treatment of cutaneous Lichen Planus. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03697460"},{"key":"10.1016\/j.anai.2026.04.015_bib0175","unstructured":"ClinicalTrials.gov. A randomized, double-blind, vehicle-controlled study of the efficacy and safety of Ruxolitinib cream in participants with cutaneous Lichen Planus. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05593432"},{"key":"10.1016\/j.anai.2026.04.015_bib0176","unstructured":"ClinicalTrials.gov. A phase 3, double-blind, randomized, vehicle-controlled, efficacy and safety study of Ruxolitinib cream in participants with hidradenitis suppurativa. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06959225."},{"key":"10.1016\/j.anai.2026.04.015_bib0177","unstructured":"ClinicalTrials.gov. A phase 3, double-blind, randomized, vehicle-controlled, efficacy and safety study of Ruxolitinib cream in participants with prurigo nodularis. Accessed February 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05755438"},{"key":"10.1016\/j.anai.2026.04.015_bib0178","unstructured":"ClinicalTrials.gov. Efficacy and safety of twice-daily application of delgocitinib cream 20 mg\/g for 6 weeks in subjects with active discoid lupus erythematosus. Accessed February 17, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03958955"},{"issue":"24","key":"10.1016\/j.anai.2026.04.015_bib0179","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0180","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2026.04.015_bib0181","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"issue":"10451","key":"10.1016\/j.anai.2026.04.015_bib0182","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0183","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"26","key":"10.1016\/j.anai.2026.04.015_bib0184","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"10209","key":"10.1016\/j.anai.2026.04.015_bib0185","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0186","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0187","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1074-7613(00)80439-2","article-title":"Stat6 is required for mediating responses to IL-4 and for development of Th2 cells","volume":"4","author":"Kaplan","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.anai.2026.04.015_bib0188","unstructured":"Sanofi. Dupixent Approved in the US as the Only Targeted Medicine to Treat Patients With Bullous Pemphigoid. Accessed February 19, 2026. Available at:https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-06-20-05-00-00-3102518"},{"key":"10.1016\/j.anai.2026.04.015_bib0189","unstructured":"Sanofi. Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD. Accessed February 19, 2026. Available at: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-03-08-18-00-00-3039375"},{"key":"10.1016\/j.anai.2026.04.015_bib0190","unstructured":"Dupilumab in the Treatment of Alopecia Areata Patients with an Atopic Background and\/or High IgE. ClinicalTrials.gov; 2022. https:\/\/clinicaltrials.gov\/study\/NCT05551793. Accessed February 19, 2026."},{"key":"10.1016\/j.anai.2026.04.015_bib0191","unstructured":"Dupilumab in the treatment of pediatric alopecia areata. ClinicalTrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05866562. Accessed February 19, 2026."},{"key":"10.1016\/j.anai.2026.04.015_bib0192","unstructured":"US National Library of Medicine. Clinical trial to evaluate efficacy and safety of dupilumab in localized scleroderma (DupiMorph). Accessed February 17, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04200755"},{"key":"10.1016\/j.anai.2026.04.015_bib0193","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jdcr.2022.10.035","article-title":"Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris","volume":"31","author":"Moore","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0194","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/pde.15779","article-title":"Pemphigus vulgaris with esophageal involvement in an atopic child successfully treated with dupilumab","volume":"42","author":"Yun","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.anai.2026.04.015_bib0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdcr.2023.09.018","article-title":"Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus","volume":"42","author":"Jiang","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0196","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/jcm14030796","article-title":"Managing the overlap: therapeutic approaches in patients with concomitant psoriasis and atopic dermatitis-a case series","volume":"14","author":"de FeliCI Del Giudice","year":"2025","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.anai.2026.04.015_bib0197","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0198","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gutjnl-2014-308004","article-title":"Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"64","author":"Danese","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.anai.2026.04.015_bib0199","unstructured":"ClinicalTrials.gov. A randomized placebo-controlled single center pilot study of the safety and efficacy of tralokinumab in subjects with moderate-to-severe alopecia areata. Accessed February 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT02684097"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0200","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ijd.17010","article-title":"Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata","volume":"63","author":"Tavoletti","year":"2024","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1016\/j.anai.2026.04.015_bib0201","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/ijd.17755","article-title":"A case of unexpected successful treatment of alopecia areata with tralokinumab in a patient with atopic dermatitis","volume":"64","author":"Kussini","year":"2025","journal-title":"Int J Dermatol"},{"issue":"7","key":"10.1016\/j.anai.2026.04.015_bib0202","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13555-023-00947-7","article-title":"Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab","volume":"13","author":"Okragly","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"10.1016\/j.anai.2026.04.015_bib0203","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2026.04.015_bib0204","unstructured":"ClinicalTrials.gov. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group study to evaluate the efficacy and safety of Lebrikizumab\/LY3650150. In: Participants With Chronic Rhinosinusitis With Nasal Polyps on Background Intranasal Corticosteroids; 2024. Accessed February 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06338995."},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0205","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate-to-severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial","volume":"161","author":"St\u00e4nder","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2026.04.015_bib0206","unstructured":"ClinicalTrials.gov. An open-label, Phase 2 study to assess the efficacy and safety of nemolizumab in subjects with systemic sclerosis. Accessed February 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05214794"},{"key":"10.1016\/j.anai.2026.04.015_bib0207","unstructured":"ClinicalTrials.gov. A 52-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of nemolizumab in adult patients with systemic sclerosis. Accessed February 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07047690"},{"issue":"1","key":"10.1016\/j.anai.2026.04.015_bib0208","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","article-title":"Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis","volume":"12","author":"Kuzumi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.anai.2026.04.015_bib0209","unstructured":"Sanofi. Sanofi\u2019s amlitelimab confirms its potential in atopic dermatitis. Accessed February 28, 2026. Available at: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2026\/2026-01-23-06-00-00-3224400"},{"issue":"10523","key":"10.1016\/j.anai.2026.04.015_bib0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(25)01865-3","article-title":"Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials","volume":"407","author":"Guttman-Yassky","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2026.04.015_bib0211","unstructured":"ClinicalTrials.gov. A phase randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to assess the efficacy, safety, and tolerability of subcutaneous amlitelimab in adult participants with moderate-to-severe asthma. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05421598"},{"key":"10.1016\/j.anai.2026.04.015_bib0212","unstructured":"ClinicalTrials.gov. A long-term extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous amlitelimab in adult participants with moderate-to-severe asthma who completed treatment period of previous amlitelimab asthma clinical study. Accessed February 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06033833"},{"key":"10.1016\/j.anai.2026.04.015_bib0213","unstructured":"ClinicalTrials.gov. A phase 2 randomized, double-blind, placebo\u2013controlled, Parallel Group, 3-arm, multinational, multicenter, proof-of-concept study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in adult participants with severe alopecia areata. Accessed February 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06444451"},{"key":"10.1016\/j.anai.2026.04.015_bib0214","unstructured":"ClinicalTrials.gov. A phase 2a\/b, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of subcutaneous amlitelimab in adult patients with nonresponsive celiac disease as an adjunct to a gluten-free diet. Accessed February 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06557772"},{"key":"10.1016\/j.anai.2026.04.015_bib0215","unstructured":"Sanofi. EADV: Sanofi\u2019s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study. Accessed February 22, 2026. Available at:https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-09-17-05-00-00-3151353."},{"key":"10.1016\/j.anai.2026.04.015_bib0216","unstructured":"ClinicalTrials.gov. A phase 2 randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of rocatinlimab in adult subjects with moderate-to-severe asthma. Accessed February 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06376045"},{"key":"10.1016\/j.anai.2026.04.015_bib0217","unstructured":"ClinicalTrials.gov. A phase 3, 52-week, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy, safety, and tolerability of rocatinlimab in adult subjects with prurigo nodularis who are inadequately controlled on topical therapies or not eligible for topical therapies. Accessed February 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06527404"},{"issue":"4","key":"10.1016\/j.anai.2026.04.015_bib0218","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0219","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","article-title":"Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"10.1016\/j.anai.2026.04.015_bib0220","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.anai.2026.04.015_bib0221","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2026.04.015_bib0222","unstructured":"Food and Drug Administration. Rinvoq (upadacitinib) prescribing information (Label No. 211675s025). Accessed February 18, 2026. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/211675s025lbl.pdf"},{"key":"10.1016\/j.anai.2026.04.015_bib0223","unstructured":"ClinicalTrials.gov. A phase 3 randomized placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06012240"},{"key":"10.1016\/j.anai.2026.04.015_bib0224","unstructured":"ClinicalTrials.gov. A phase 3 randomized placebo-controlled, double-blind study to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with alopecia areata and at least 25% scalp hair loss. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07023302"},{"key":"10.1016\/j.anai.2026.04.015_bib0225","unstructured":"ClinicalTrials.gov. A phase 3 randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with moderate-to-severe hidradenitis suppurativa who have failed anti-TNF therapy. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05889182"},{"key":"10.1016\/j.anai.2026.04.015_bib0226","unstructured":"SELECT. SLE: a phase 3 program to evaluate the safety and efficacy of upadacitinib in subjects with moderately to severely active SLE. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05843643"},{"key":"10.1016\/j.anai.2026.04.015_bib0227","unstructured":"ClinicalTrials.gov. A phase 3 randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety, and tolerability of upadacitinib in adult and adolescent subjects with non-segmental vitiligo who are eligible for systemic therapy. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06118411"},{"key":"10.1016\/j.anai.2026.04.015_bib0228","unstructured":"ClinicalTrials.gov. A 24 week, open-label study to evaluate the efficacy and safety of upadacitinib in patients with moderate-to-severe prurigo nodularis. Accessed February 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06773403"},{"key":"10.1016\/j.anai.2026.04.015_bib0229","unstructured":"Food and Drug Administration. Olumiant (baricitinib) prescribing information (Label No. 207924s007). Accessed February 18, 2026. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s007lbl.pdf"},{"key":"10.1016\/j.anai.2026.04.015_bib0230","unstructured":"ClinicalTrials.gov. A phase 3 multicenter study to evaluate the long-term safety and efficacy of baricitinib in patients from 1 year to <18 years of age with juvenile idiopathic arthritis (JIA). Accessed February 17, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03773965"},{"key":"10.1016\/j.anai.2026.04.015_bib0231","unstructured":"ClinicalTrials.gov. Open-label, randomized study with a tocilizumab reference arm to evaluate safety, efficacy and pharmacokinetics of baricitinib in children from 1 to less than 18 years of age with systemic juvenile idiopathic arthritis. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04088396"},{"key":"10.1016\/j.anai.2026.04.015_bib0232","unstructured":"ClinicalTrials.gov. A randomized, double-blind, placebo-controlled, withdrawal, safety and efficacy study of oral baricitinib in patients from 2 years to less than 18 years old with juvenile idiopathic arthritis (JIA). Accessed February 17, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03773978"},{"key":"10.1016\/j.anai.2026.04.015_bib0233","unstructured":"ClinicalTrials.gov. Safety and efficacy of baricitinib on skin tightening in diffuse cutaneous systemic sclerosis: a comparative study with methotrexate. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06936215"},{"key":"10.1016\/j.anai.2026.04.015_bib0234","unstructured":"ClinicalTrials.gov. A phase 3, double-blind, randomized, placebo-controlled study of baricitinib to delay Stage 3 type 1 diabetes in at-risk participants aged \u22651 to <36 years. ClinicalTrials.gov; 2025. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07222137"},{"key":"10.1016\/j.anai.2026.04.015_bib0235","unstructured":"ClinicalTrials.gov. A phase A 3, double-blind, randomized, placebo-controlled study of baricitinib to preserve beta cell function in participants newly diagnosed with type 1 diabetes aged \u22651 to <36 years. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07222332"},{"key":"10.1016\/j.anai.2026.04.015_bib0236","unstructured":"ClinicalTrials.gov. Baricitinib in patients with relapsing or na\u00efve dermatomyositis: a multicenter randomized controlled trial (bird). Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04972760"},{"key":"10.1016\/j.anai.2026.04.015_bib0237","unstructured":"Eli Lilly and Company Updates on OLUMIANT\u00ae (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis. Accessed February 20, 2026. Available at: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/updates-olumiantr-baricitinib-phase-3-lupus-program-and-fda"},{"key":"10.1016\/j.anai.2026.04.015_bib0238","unstructured":"ClinicalTrials.gov. Use of specific JAK inhibition on inflammatory skin and scalp diseases in Down syndrome R61AR084210. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07242638"},{"key":"10.1016\/j.anai.2026.04.015_bib0239","unstructured":"ClinicalTrials.gov. Efficacy, safety, and tolerability of abrocitinib for reducing pruritus in adults with prurigo nodularis and chronic pruritus of Unknown origin. Accessed on Accessed February 17, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05038982"},{"key":"10.1016\/j.anai.2026.04.015_bib0240","unstructured":"ClinicalTrials.gov. A phase 2 multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of subtype-selective JAK inhibitors for preservation of pancreatic \u03b2 cell function in newly diagnosed type 1 diabetes mellitus. Accessed February 19, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05743244"},{"key":"10.1016\/j.anai.2026.04.015_bib0241","unstructured":"Food and Drug Adminstration. XELJANZ (tofacitinib) prescribing information (Label Nos. 203214s039, 213082s011). Accessed February 18, 2026. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/203214s039%2C213082s011lbl.pdf"},{"issue":"3","key":"10.1016\/j.anai.2026.04.015_bib0242","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.04.015_bib0243","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2026.04.015_bib0244","unstructured":"Food and Drug Adminstration. Janus kinase (JAK) inhibitors: drug safety communication\u2014FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death. Accessed February 17, 2026. Available at:https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626001626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626001626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:16:55Z","timestamp":1782465415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626001626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":244,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1081120626001626"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.04.015","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidities of atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}